Name : Cynomolgus CD96/TACTILE Protein
Product Source :
Recombinant Cynomolgus CD96/TACTILE Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Val22-Gly502.[Accession | A0A2K5TWV6]
Molecular Weight :
The protein has a predicted MW of 54.27 kDa. Due to glycosylation, the protein migrates to 80-130 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Cynomolgus CD96 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Cynomolgus CD96 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Cynomolgus CD96, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Anti-CD96 Antibody, hFc Tag with the EC50 of 0.93μg/ml determined by ELISA.
Background :
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
Synonyms :
CD96 molecule; CD96; DKFZp667E2122; TACTILE
References & Citations :
(1) Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. doi: 10.1158/1078-0432.CCR-16-0933. Epub 2016 Sep 12. PMID: 27620276.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CXCL16 Proteinmanufacturer
RIOK1 ProteinPurity & Documentation
Popular categories:
CCL6
Alpha-1 Antitrypsin 1-1